t ra n s gene at the messenger ri b o nu cleic acid level (unpublished data), and we have shown that they are ACTH prod u c i n g. 4, 5 H e re we rep o rt that these tra n s genic mice, as well as immunocompetent histocompat i ble mice carrying subcutaneous transplants of the pituitary tumors have p at h o l ogi c a l ly increased levels of ACTH in plasma, and we describe some accompanying biological effects of b o dy weight, blood glucose, and water balance. Both the t ra n s genic mice and those with tumor transplants display h i s t o p at h o l ogical and endocri n o l ogical fe at u res that make them re l evant models for studying Cushing's disease in h u m a n s .
Materials and Methods

Transgenic Mice
Transgenic mice were generated by microinjection of the polyoma early region promoter linked to the cDNA-encoding PyLT into the male pronuclei of fertilized eggs. 1 Transgenic pups in a litter were identified by the presence of PyLT in genomic DNA isolated from tail biopsies taken at 2 weeks of age. 1 Nontransgenic siblings were used as control animals in this study. The mice were kept in a facility with humidified and filtered air together with other transgenic lineages approved by the American Association for Accreditation for Laboratory Animal Care. They had access to food and water ad libitum, and were inspected daily. The mice were anesthetized with an intraperitoneal injection of 0.65 ml 2.5% avertin per 30 g animal weight.*
Transplant Mice
Pituitary tumors from the transgenic animals (PyLT-1) were minced with sterile scalpel blades and forced through a 19-gauge hypodermic needle. Then, 0.1 ml tumor slurry was injected subcutaneously into young B6D2F1 nontransgenic female mice † and passaged four times. In addition, another fourth passage was set up using tissue cubes approximately 2 mm in size instead of the tumor s l u r r y .
In each experiment four to 15 test animals received transplants and three to five mice that did not receive tumor were used as controls. All mice receiving transplants were females, except in the third passage, in which both genders were used. The mice receiving transplanted tissue cubes were weighed every 2 weeks, starting on the day of the transplantation. The implant site was inspected regularly and from the time a tumor was palpable, the experimental and the control mice were anesthetized every 2nd week and two perpendicular tumor diameters were measured with calipers. Tumor volumes were calculated according to the formula 0.5 ϫ length ϫ w i d t h 2 , and growth curves were constructed. 3 
Blood Sampling
Blood samples for a time-course study were obtained by sacrificing transgenic mice at ages 4 and 9 months together with their ageand sex-matched controls. In addition, blood was withdrawn from all mice that became clinically ill during the experiment. Each age group contained four to five experimental and three to six control animals of each gender. The mice that received transplanted tumor were sacrificed at ages 6 months (third passage, six females), 9 months (third passage, two males and three females), and approximately 12 months (second passage, five females). All blood samples were withdrawn between noon and 4 p.m. Two 9-month-old mice with third passage transplants were sacrificed at 2 and 7 weeks after their tumors were removed for establishing the fourth passage s e r i e s .
Animals were brought from the animal room to a separate autopsy room 2 hours or more prior to autopsy. Autopsies were started and completed between noon and 4 p.m. A heart puncture was performed in anesthetized mice with a 1-ml syringe and 22-gauge hypodermic needle prerinsed with 1000 U/ml heparin. After sampling, the mice died of hypovolemia. The blood was transferred to chilled microfuge tubes and immediately centrifuged at 8000 rpm for 10 minutes. The plasma was transferred to clean, chilled microfuge tubes and stored at Ϫ7 0 ° C .
Analysis of ACTH
Levels of ACTH in plasma were measured using a double-antibody radioimmunoassay.
1 0 For these analyses, human ACTH antiserum (AFP 6328031), human ACTH for iodination (AFP 2938C), and rat reference preparation (rACTH-RP-1) were used.
Blood Glucose Levels
Blood glucose was measured with Glucofilm test strips and a glucometer. ‡ Mice were held by the tail in a restrainer, and 1 to 2 mm of the distal part of the tail was excised. One drop of blood was placed on the strip, and the glucose level was measured according to the manufacturer's instructions. Normal control samples were used to test the system for each new batch of test strips. The mice were denied food and water the night before the sampling. In one study, fasting blood glucose levels were measured at 8 a.m. in three female and three male PyLT-1 transgenic mice regularly for 3 months from the age of 9 months. In another experiment, a glucose tolerance test was performed on mice with 7-month-old third passage pituitary tumors. Nine tumor-bearing and six control mice of each sex were denied food and water overnight, and at 8 a.m. the blood glucose level was measured. Thereafter, 1 mg glucose per gram body weight was injected intraperitoneally, and blood glucose levels were measured hourly for 4 hours.
Urine Output
Groups of two to four mice were kept in metabolic cages for mice § for 3 to 4 days. The inner funnel of the cage was coated with P r o s i l -2 8 according to the manufacturer's instructions. Water intake in milliliters and urinary output in grams were measured every 24 hours.
Hormone Receptor Analyses
Tumor material from 9-month-old mice transplanted 8 months earlier with third passage PyLT-1 pituitary tumors was used. The mice, three males and three females, had 10-to 22-mm large subcutaneous transplant tumors. One primary pituitary tumor from a sick PyLT-1 female was also investigated. The tumor material or pituitary glands were immediately put into microfuge tubes, frozen in liquid nitrogen, and stored at Ϫ20°C. Cryostat sections were cut and used for estrogen and progesterone receptor staining, using kits and recommendations from the manufacturer.* Positive and negative control samples were included.
Statistical Analysis
The relationship between the quantitative findings in the experimental and the control animal groups was evaluated nonparametrically using the Mann-Whitney two-sample test in a graphics program. † A value of p Ͻ 0.05 was considered significant.
Results
Clinical Symptoms and Pathology
To study the time course of the morp h o l ogical and the e n d o c ri n o l ogical ch a n ges, symptom-free tra n s genic mice at 4 and 9 months of age we re studied in addition to sympt o m atic tra n s genic mice and compared to mat ch e d, nont ra n s genic controls. When the mice became cl i n i c a l ly ill t h ey developed a spinal hump in the thoracic region and an u n s t e a dy gait, and they had difficulty in re a ching food and wat e r. Sick mice deteri o rated rap i d ly and we re killed. Th e mean age at the time of autopsy for these animals was 15.5 months for males and 13.1 months for fe m a l e s . 4 All cl i n i c a l ly ill PyLT-1 tra n s genic mice had large pitui t a ry tumors (ap p rox i m at e ly 5 mm in gre atest diameter) t h at compressed neighboring stru c t u res (Fi g. 1A). Mic ro s c o p i c a l ly the tumors we re ch a ra c t e ri zed by nests and c o rds of tumor cells with minimal atypia and few mitotic fi g u res (Fi g. 1B). The tumors we re surrounded by a A. Helseth, et al. p s e u d o c ap s u l e, and inva s ive growth into the brain pare n chyma was not detected. The mice that re c e ived tra n splants had subcutaneous tumors of a similar histopat h o logy but mitoses we re easily identified and gre ater in nu m b e r. In mice with large transplanted tumors, fo c a l a reas of intrat u m o ral necrosis we re ap p a rent. The tumor cells we re tested for immu n o re a c t ivity against a bat t e ry of a n t e rior pituitary peptides as rep o rted prev i o u s ly. 4 , 5 M a ny 
we re similar in the pri m a ry and the tra n splanted tumors . Table 1 gives the plasma ACTH concentrations in c o n t rol, tra n s ge n i c, and transplanted mice according to age and sex. The median ACTH values for 12-month-old female tra n s ge n i c, transplant, and control mice have been p u blished prev i o u s ly. 4 The baseline value was less than 10 g/L ACTH in plasma of the control mice of both sexe s and in all age groups studied. In 4-month-old tra n s ge n i c mice none of the samples showed increased ACTH leve l s . At 9 months, a moderate increase was seen in three of four samples from males, and in one of the four samples f rom females a marke d ly increased hormone level wa s found (170 g/L). The latter sample was from the only 9-month-old mouse with a microadenoma. Both male and female cl i n i c a l ly ill (Ͼ 12 months) tra n s genic mice had s i g n i fi c a n t ly elevated ACTH levels re l at ive to the contro l animals. Furt h e rm o re, the cl i n i c a l ly ill female PyLT-1 mice had signifi c a n t ly higher plasma ACTH concentrations than the corresponding male mice (p = 0.0275).
Plasma ACTH Levels
All but one of the 6-month-old mice with tra n s p l a n t e d t u m o rs had marke d ly increased ACTH levels in plasma, in c o n t rast to the situation in 4-month-old tra n s genic mice. The one 6-month-old animal with a normal value had no p a l p able tumor at the time of autopsy, but a small tumor (1-2 mm) was found by dissection and confi rmed histol ogi c a l ly to be adenomatous tissue. 4 Tu m o rs from two female tumor-b e a ring mice we re used for establishing a fo u rth passage series of tumor transplants. These donor mice we re subjected to autopsy and blood sampling 2 and 7 weeks after their tumors we re re m oved for passagi n g. The ACTH findings in these two mice we re 109 g/L (2 weeks) and 21 g/L (7 we e k s ) .
The ACTH data in Table 1 show that PyLT-1 tra n s ge n i c mice with micro-or macroadenomas of the pituitary had s i g n i fi c a n t ly increased levels of ACTH in the bl o o d. Th e i m munocompetent mice with subcutaneous tumor tra n splants had even higher ACTH leve l s .
Blood Glucose Levels
Patients with Cushing's disease may develop hy p e rg lycemia and diabetes. We there fo re studied the fa s t i n g blood glucose levels in PyLT-1 tra n s genic mice from the age of 8 through 12 months to analy ze possible blood glucose responses to the pat h o l ogical ACTH output from the t u m o r. The data in Table 2 show that there was no significant increase in glucose levels in the age period cove ri n g neoplastic tra n s fo rm ation in the pituitary gland. This indic ates that the increased ACTH secretion in PyLT-1 tra n sgenic mice had no significant impact on the fasting bl o o d glucose leve l s .
In the glucose tolerance test, mice with tra n s p l a n t e d t u m o rs we re compared to B6D2F1 control mice. The cont rol mice show a phy s i o l ogical response to the glucose ch a l l e n ge with re t u rn to the fasting level after ap p rox im at e ly 2 hours (Table 3 ). The transplant mice show a similar response but the mean glucose level is higher at each time point. The diffe rence is significant at each point in spite of the wide ra n ge of the results in the tumor gro u p . This finding indicates that the transplant mice have a s t ressed carbohy d rate metabolism with hy p e rg ly c e m i a , but ove rt diabetes mellitus with a delayed re t u rn to fa s t i n g l evel after glucose ch a l l e n ge has not occurre d.
Urine Output
The adrenal production of glucocorticoids, and to a lesser extent the minera l c o rticoids, are reg u l ated by ACTH. It was there fo re of interest to examine wh e t h e r i n c reased ACTH levels had consequences for uri n a ry out-A. Helseth, et al. put and water intake. At 6 months of age, prior to symptoms and signs of neoplastic tra n s fo rm ation in the pitui t a ry, no diffe rence was found between PyLT-1 and contro l animals ( Table 4 ). In 10-month-old tra n s genic mice, howeve r, the urine output and water intake we re significant-ly reduced compared to both control mice and yo u n ge r P y LT-1 animals.
Tumor Growth and Body Weight Changes
To quantitate the growth rate of the transplant tumors , mice with fo u rth passage tumors (cubes) we re studied. The mean tumor volume is presented in Fi g. 2. By 82 day s after inoculation the volume was 38 mm 3 and incre a s e d s l i g h t ly until ap p rox i m at e ly 105 days. Th e re a f t e r, a steady i n c rease in the tumor volume was observed with a calc u l ated doubling time of ap p rox i m at e ly 6 days. Th e sigmoid shape of the growth curve re s e m bles cl o s e ly the Gompertzian growth pat t e rn typically seen in solid t u m o rs . 1 1 Patients with Cushing's disease usually gain we i g h t .
We studied the body weight of mice with fo u rth passage t ransplant tumors. No weight diffe rence was found bet ween mice with transplanted tumors and age -m at ch e d c o n t rol animals until ap p rox i m at e ly 95 days after tumor i n o c u l ation (Fi g. 2) . From this point, howeve r, the we i g h t of the transplant mice increased signifi c a n t ly re l at ive to t h at of the control animals. Both male and female mice d eveloped a neck hump of increased fat deposition, and this sign was more ap p a rent in the female mice. Toge t h e r, the data show that when the subcutaneous tumors we re e s t abl i s h e d, with a mean tumor volume of ap p rox i m at e ly 50 mm 3 , the transplant mice responded with a pat h o l ogical weight incre a s e.
Sex Hormone Receptors
Because of the observed diffe rences in the age of onset of symptoms and tumor size between male and fe m a l e P y LT-1 tra n s genic mice, 4 we examined tumor cells fo r the presence of estrogen or proge s t e rone re c ep t o rs. Immu n o cy t o chemical studies did not detect such re c ep t o rs in p ri m a ry pituitary tumors or in transplanted tumors (dat a not shown). The indications of biological diffe rences in tumor development between the sexes, there fo re, may not be re l ated to such sex hormone re c ep t o rs .
Discussion
The present study demonstrates that PyLT-1 tra n s ge n i c mice as well as mice re c e iving tumor transplants have some of the metabolic and endocrine disturbances ch a ra c t e ristic of Cushing's disease. All tumor-b e a ring mice s h owed pat h o l ogi c a l ly increased plasma ACTH leve l s cl e a rly associated with the growth of the PyLT-1 pituitary t u m o rs in the animals. A small increase in fasting bl o o d glucose levels was found in mice with transplanted tum o rs. Mice with transplanted tumors increased their body weight beyond the corresponding control mice from the time the subcutaneous tumors we re palpabl e. These fi n dings are indicat ive of biological responses to incre a s e d ACTH in tra n s genic and transplant mice.
S eve ral tra n s genic lineages of animals with va rious promoter/enhancer regions and oncogenes develop pituitary t u m o rs. It is unclear whether the pituitary gland is a prefe rred site for neoplasia in tra n s genic systems. Murp hy, e t a l ., 9 h ave rep o rted a model that mimics human mu l t i p l e e n d o c rine neoplasia by using the upstream sequences of the bovine va s o p ressin gene linked to simian virus-40 T a n t i gen. Their mice developed pancre atic B-cell tumors and pituitary tumors with pleomorphic nu clei and fre q u e n t mitotic fi g u res. Wi n d l e, et al., 1 3 used the same oncoge n e under the reg u l ator control of the human gly c o p rotein hormone ␣ s u bunit. Their mice developed anterior pituitary t u m o rs, and a clonal cell line from the tumor secreted ␣ s u bunit protein. Thus, this system re s e m bles the class of human anterior pituitary tumors termed nonfunctioning adenomas. In a third model, pituitary hy p e rplasia with ele-vated serum growth hormone levels and clinical gi ga n t i s m was demonstrated in tra n s genic mice with a rat grow t h h o rmone pro m o t e r -ch o l e ra toxin constru c t . 2 Thus, tra n sgenic mouse models are ava i l able for the study of va ri o u s human diseases involving the anterior pituitary: mu l t i p l e e n d o c rine neoplasia, 9 nonfunctional pituitary adenomas, 1 3 gi ga n t i s m , 2 and Cushing's disease. To measure ACTH in mouse plasma we used an assay for rodent ACTH employing a rat re fe rence prep a rat i o n . The assay used for human samples was unsuitabl e because of the low affinity of the human antibody fo r mouse ACTH, as detected in a pilot study (data not s h own). Sick PyLT-1 mice we re found to have pat h o l ogic a l ly raised plasma ACTH levels, median 180 g/L in males and 685 g/L in females. Another tra n s genic line age with the cort i c o t ro p i c -releasing factor (CRF) ge n e under the control of the metallothionein promoter has been rep o rted by Stenze l -Po o re, et al. 1 2 These tra n s ge nic mice also displayed physical and endocri n o l ogi c a l ch a n ges similar to those of patients with Cushing's d i s e a s e.
Tra n s gene ex p ression in the cells ex p ressing the e n d ogenous CRF gene and plasma levels of ACTH we re e l evated five fold compared to the control animals in the s t u dy by Stenze l -Po o re, et al. 1 2 Wh e reas the CRF tra n sgenic mice had an ACTH mean at 100 pg/ml, our assay gave a data set in a completely diffe rent concentrat i o n ra n ge. Although the ACTH results for CRF tra n s ge n i c s re s e m ble the human data for pituitary adenomas, the ra n ge seen for the PyLT-1 tra n s genics and the transplants can be found in human patients with ectopic ACTH secre t i o n . One important factor to be considered is the inhere n t s t ress at sampling. 6 Our blood sampling pro c e d u re exposed the animals to higher stress levels. Thus, our dat a rep resent stress responses in the va rious groups and age s . E ven so, the data corre l ate with the histopat h o l ogical fi n dings in that mice with no pat h o l ogical ch a n ges in their p i t u i t a ries had low plasma ACTH levels, and PyLT-1 mice 9 months and older with micro-and macro a d e n o m a s s h owed dra m atic increases in plasma AC T H . 4 The data indicate a possible sex diffe rence in the PyLT-1 tra n s genic mice. Clinically ill female mice have signific a n t ly higher ACTH values than the males, the mean life span was somewh at shorter in female PyLT-1 compared to males, and the subcutaneous tumor transplants re a ched a l a rger maximum tumor diameter in female re c i p i e n t s . 4 We there fo re raised the question of whether diffe re n t i a l ex p ression of estrogen or proge s t e rone re c ep t o rs could be i nvo l ved in the sex diffe rences. Howeve r, we did not detect these re c ep t o rs in the pituitary or transplant tumors , c o n t ra ry to a finding in a previous rep o rt on human pitui t a ry tumors .
